韩国专利KR20020004974A Methods for The Preparation of Biphenyl Isoxazole Sulfonamides

专利PDF首页>>韩国专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
The present invention relates to a process for preparing biphenyl isoxazole sulfonamide and intermediates thereof. The present invention also relates to novel intermediates produced by this method. Biphenyl isoxazole sulfonamides prepared by the method are particularly useful endothelin antagonists in the treatment of hypertension, congestive heart failure and male erectile dysfunction.
公开号:KR20020004974A
申请号:KR1020017011870
申请日:2000-03-02
公开日:2002-01-16
发明作者:암베리쉬 싱；치엔-쿠앙 첸；존 에이. 그로소；에드워드 제이. 델라니；슈에바오 왕；리차드 피. 폴니아스젝；존 케이. 토타틸
申请人:스티븐 비. 데이비스；브리스톨-마이어스스퀴브컴파니；
IPC主号:

专利说明:

Method for the preparation of Biphenyl Isoxazole Sulfonamides
[1] The present invention relates to a process for the preparation of biphenyl isoxazole sulfonamide and intermediates thereof. The present invention also relates to novel intermediates produced by this method. Biphenyl isoxazole sulfonamides prepared by the method are particularly useful endothelin antagonists in the treatment of hypertension.
[2] <Overview of invention>
[3] The present invention makes it possible to prepare biphenyl sulfonamides of the general formula (I), enantiomers and diastereomers thereof, and salts, preferably pharmaceutically acceptable salts.
[4]
[5] Where
[6] The phenyl ring of the biphenyl group can be independently unsubstituted or substituted with one or more substituents.
[7] Preferred substituents for the biphenyl group include the groups R ¹¹ to R ¹⁴ described herein, particularly when the biphenyl group is a 2-biphenyl group, There is a flag. Preferred methods of the present invention allow the preparation of compounds of formula (Ia), enantiomers and diastereomers thereof, and salts, preferably pharmaceutically acceptable salts thereof.
[8]
[9] Throughout this specification, the symbols are defined as follows.
[10] One of X and Y is N and the other is O;
[11] R ¹ , R ² , R ³ and R ⁴ are each directly bonded to the ring carbon, and each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) -C (O) H or -C (O) R ⁵ ; (h) -CO ₂ H or -CO ₂ R ⁵ ; (i) -Z ⁴ -NR ⁶ R ⁷ ; (j) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ ; Or (k) R ³ and R ⁴ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ so that together with the carbon atoms to which they are attached 4 to 8 membered saturated, unsaturated or aromatic Can complete the ring;
[12] R ⁵ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl which may be substituted with Z ¹ , Z ² and Z ³ ;
[13] R ⁶ , R ⁷ , R ⁸ , R ⁹ and R ¹⁰ are each independently (a) hydrogen; Or (b) alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl which may be substituted with Z ¹ , Z ² and Z ³ ; or
[14] R ⁶ and R ⁷ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ to complete a 3-8 membered saturated or unsaturated ring with the nitrogen atom to which they are attached ; Or any two of R ⁸ , R ⁹ and R ¹⁰ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ , together with the atoms to which they are attached Complete saturated or unsaturated rings;
[15] R ¹¹ , R ¹² , R ¹³ and R ¹⁴ are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) heterocycles, substituted heterocycles or heterocyclooxy; (d) halo; (e) hydroxyl; (f) cyano; (g) nitro; (h) —C (O) H or —C (O) R ⁵ ; (i) -CO ₂ H or -CO ₂ R ⁵ ; (j) -SH, -S (O) _n R ⁵ , -S (O) _m -OH, -S (O) _m -OR ⁵ , -OS (O) _m -OR ⁵ , -OS (O) _m OH or —OS (O) _m —OR ⁵ ; (k) -Z ⁴ -NR ⁶ R ⁷ ; Or (l) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ ;
[16] Z ¹ , Z ² and Z ³ are each independently (a) hydrogen; (b) halo; (c) hydroxy; (d) alkyl; (e) alkenyl; (f) aryl; (g) aralkyl; (h) alkoxy; (i) aryloxy; (j) aralkoxy; (k) heterocycles, substituted heterocycles or heterocyclooxy; (l) -SH, -S (O) _n Z ⁶ , -S (O) _m -OH, -S (O) _m -OZ ⁶ , -OS (O) _m -Z ⁶ , -OS (O) _m OH or —OS (O) _m —OZ ⁶ ; (m) oxo; (n) nitro; (o) cyano; (p) —C (O) H or —C (O) Z ⁶ ; (q) -CO ₂ H or -CO ₂ Z ⁶ ; (r) -Z ⁴ -NZ ⁷ Z ⁸ ; (s) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -H; (t) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -Z ⁶ ; Or (u) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -NZ ⁷ Z ⁸ ;
[17] Z ⁴ and Z ⁵ are each independently (a) a single bond; (b) Z ⁹ -S (O) _n -Z ^10- ; (c) Z ⁹ -C (O) -Z ^10- ; (d) Z ⁹ -C (S) -Z ^10- ; (e) Z ⁹ -OZ ^10- ; (f) Z ⁹ -SZ ^10- ; (g) Z ⁹ -OC (O) -Z ^10- ; Or (h) Z ⁹ -C (O) -OZ ^10- ;
[18] Z ⁶ is alkyl; Alkyl substituted with 1 to 3 groups selected from halogen, aryl, aryloxy and alkoxy; Alkenyl; Alkynyl; Cycloalkyl; Cycloalkyl substituted with 1 to 3 groups selected from alkyl, aryl, alkenyl and alkoxyaryl; Cycloalkyl to which benzene ring is fused; Aryloxy substituted with one or two halogens; Cycloalkylalkyl; Cycloalkenyl; Cycloalkenylalkyl; Aryl; Aryl substituted with 1 to 4 groups or methylenedioxy selected from alkyl, dialkylamino, cyano, halogen, trihaloalkyl, alkoxy and trihaloalkoxy; Or a hetero ring or a substituted hetero ring;
[19] Z ⁷ and Z ⁸ are each independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl or Z ⁷ and Z ⁸ together form alkylene or alkenylene to which nitrogen to which they are attached Together with atoms to complete a 3-8 membered saturated or unsaturated ring;
[20] Z ⁹ and Z ¹⁰ are each independently a single bond, alkylene, alkenylene or alkynylene;
[21] Z ¹¹ is (a) hydrogen; Or (b) alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl substituted with alkyl, 1, 2 or 3 halogen; or
[22] Any two of Z ⁷ , Z ⁸ and Z ¹¹ together form an alkylene or alkenylene to complete a three to eight membered saturated or unsaturated ring with the atoms to which they are attached;
[23] J is O, S, N or NR ¹⁵ ;
[24] K and L are N or C, provided that at least one of K or L is C;
[25] R ¹⁵ is hydrogen, alkyl, hydroxyethoxy methyl or methoxyethoxy methyl;
[26] m is each independently 1 or 2;
[27] n is each independently 0, 1 or 2;
[28] p is 0 or an integer of 1 or 2.
[29] According to the invention, the compound of formula (I) or a salt thereof is (a) an arylboronic acid of formula (II) or a pina thereof in the presence of a palladium (0) catalyst and a base containing an alkali metal atom selected from sodium, potassium or lithium A call ester or salt is contacted with a halophenyl compound of formula III or a salt thereof to form a compound of formula IV or a salt thereof, and the compound of formula IV or a salt thereof as a chlorinating agent to a compound of formula Converting; And
[30] (b) in the presence of a base, coupling a compound of Formula (V) or a salt thereof with a compound of Formula (VI) to form a compound of Formula (I) or a salt thereof.
[31]
[32] Where
[33] R is an alkyl group,
[34] The phenyl ring of formula (II) may be further substituted, for example, with one or more groups described in the above R ¹¹ to R ¹⁴ groups.
[35]
[36] Where
[37] Halo groups are preferably bromo or iodo,
[38] The phenyl ring of formula III can be further substituted, for example, with one or more groups described in groups R ¹¹ to R ¹⁴ above, especially when the biphenyl group of the compound of formula I or a salt thereof is 2-biphenyl The group is in para position relative to the halo group.
[39]
[40]
[41] Where
[42] The phenyl ring of the biphenyl group of formula IV or formula V may be independently unsubstituted or substituted with one or more substituents;
[43] M is sodium, potassium or lithium.
[44]
[45] In a preferred embodiment, the compound of formula (Ia) or a salt thereof comprises (a) a boronic acid of formula (IIa) or a salt thereof in the presence of a palladium (0) catalyst and a base containing an alkali metal atom selected from sodium, potassium or lithium Contacting with a halophenyl compound of formula IIIa or a salt thereof to form a compound of formula IVa or a salt thereof and converting the compound of formula IVa to a compound of formula Va with a chlorinating agent; And
[46] (b) in the presence of a base, coupling a compound of formula Va or a salt thereof with a compound of formula VI to form a compound of formula la or a salt thereof.
[47]
[48] Where
[49] R is an alkyl group.
[50]
[51]
[52] Where
[53] M is lithium, sodium or potassium.
[54]
[55] The process of the invention for preparing the compounds of formula (I) or salts thereof is advantageous in that it provides a high yield with minimal formation or no production of impurities.
[56] The invention also provides novel intermediates of the process of the invention, for example the compounds of the formulas II, IV, V, VIII and XII, and novel methods for preparing such intermediates. The aforementioned step (b), ie the coupling of the compound of the formula V with the compound of the formula VI, is itself a novel step and a further embodiment of the invention.
[57] The invention is further described as follows. Definitions of terms used herein are described below. These definitions apply to terms such as those used individually or as part of another group throughout this specification unless otherwise indicated.
[58] The term "alkyl" or "alk-" refers to a straight or branched chain hydrocarbon group of 1 to 10 carbon atoms, preferably 1 to 7 carbon atoms. The expression "lower alkyl" refers to an alkyl group having 1 to 4 carbon atoms.
[59] The term "alkoxy" refers to alkyl-O-.
[60] The term "chlorinating agent" is used herein as "Vilsmeier," which can be formed by the reaction of an agent that supplies chlorine, for example dimethylchloromethyleneammonium chloride (e.g., dimethyl formamide and oxalyl chloride). Reagent, "and phosphorus pentachloride, oxalyl chloride or thionyl chloride.
[61] The term "alcohol" refers to alcohols having 1 to 7 carbon atoms, in particular alkyl alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, butyl alcohol and the like.
[62] The term "aryl" or "ar-" refers to phenyl, naphthyl and biphenyl.
[63] The term "alkenyl" refers to a straight or branched chain hydrocarbon group of 2 to 10 carbon atoms having one or more double bonds. Groups having 2 to 4 carbon atoms are preferred.
[64] The term "alkynyl" refers to a straight or branched chain hydrocarbon group of 2 to 10 carbon atoms having one or more triple bonds. Groups having 2 to 4 carbon atoms are preferred.
[65] The term "alkylene" refers to a straight chain bridge of 1 to 5 carbon atoms linked by a single bond, which may be substituted with 1 to 3 lower alkyl groups (e.g.,-(CH ₂ ) _x -wherein x is 1 to 5) Point to.
[66] The term "alkenylene" refers to a straight chain bridge having 2 to 5 carbon atoms having 1 or 2 double bonds, which may be linked by a single bond and substituted with 1 to 3 lower alkyl groups. Examples of alkenylene groups include —CH═CH—CH═CH—, —CH ₂ —CH═CH—, —CH ₂ —CH═CH—CH ₂ —, —C (CH ₃ ) ₂ CH═CH— and — CH (C ₂ H ₅ ) -CH = CH-.
[67] The term "alkynylene" refers to a straight chain bridge of 2 to 5 carbon atoms having a triple bond, which may be linked by a single bond and substituted with 1 to 3 lower alkyl groups. Examples of alkynylene groups are -C≡C-, -CH ₂ -C≡C-, -CH (CH ₃ ) -C≡C- and -C≡C-CH (C ₂ H ₅ ) CH _2- .
[68] The term "alkanoyl" refers to a group of the formula -C (O) alkyl.
[69] The terms "cycloalkyl" and "cycloalkenyl" refer to cyclic hydrocarbon groups of 3 to 8 carbon atoms.
[70] The term "hydroxyalkyl" refers to an alkyl group comprising one or more hydroxy radicals, such as -CH ₂ CH ₂ OH, -CH ₂ CH ₂ OHCH ₂ OH, -CH (CH ₂ OH) ₂ , and the like.
[71] The terms "halogen" and "halo" refer to fluorine, chlorine, bromine and iodine.
[72] The terms "heterocycle", "heterocyclic" and "heterocyclo" refer to optionally substituted, fully saturated or unsaturated, aromatic or non-aromatic cyclic groups, for example one or more heteroatoms in one or more carbon atom-containing rings. It refers to a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic or 10 to 15 membered tricyclic ring system having an atom. Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atom, oxygen atom or sulfur atom, wherein nitrogen and sulfur heteroatoms may be optionally oxidized, and nitrogen heteroatoms May optionally be quaternized. Heterocyclic groups may be bonded to any heteroatom or carbon atom.
[73] Examples of monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazoli Neil, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-jade Sofiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazinyl, azepinyl, 4-piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetra Hydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like.
[74] Examples of bicyclic heterocyclic groups include indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, tetra-hydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyra Nil, indolinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cynolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (e.g. furo [2,3-c] pyri) Diyl, furo [3,2-b] pyridinyl or furo [2,3-b] pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (e.g. 3,4-dihydro-4-oxo-quina Zolinyl), tetrahydroquinolinyl and the like.
[75] Examples of tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenantridinyl, xanthenyl and the like.
[76] The expression "substituted heterocycle" means one, two or three (a) alkyls, in particular lower alkyl; (b) hydroxy (or protected hydroxy); (c) halo; (d) oxo (ie = O); (e) amino, alkylamino or dialkylamino; (f) alkoxy; (g) carbocycles such as cycloalkyl; (h) carboxy; (i) heterocyclooxy; (j) alkoxycarbonyl, such as unsubstituted lower alkoxycarbonyl; (k) carbamyl, alkylcarbamyl or dialkylcarbamyl; (l) mercapto; (m) nitro; (n) cyano; (o) carboalkoxy; (p) sulfonamido, sulfonamidoalkyl or sulfonamidodialkyl; (q) ; (r) ; (s) aryl; (t) alkylcarbonyloxy; (u) arylcarbonyloxy; (v) arylthio; (w) aryloxy; (x) alkylthio; (y) formyl; (z) arylalkyl; Or (a ') a heterocycle substituted with aryl substituted with alkyl, cycloalkyl, alkoxy, hydroxy, amino, alkylamino, dialkylamino, halo or trihaloalkyl.
[77] The term "heterocyclooxy" refers to a heterocyclic group bonded via an oxygen bridge.
[78] The term "his pinacol ester" Group represents a compound present in place of the boronic acid group -B (OH) ₂ .
[79] Throughout the specification, groups and substituents thereof may be selected to provide stable moieties and compounds.
[80] Compounds of formula (I) and their intermediates may form salts that are also within the scope of the present invention. Pharmaceutically acceptable (ie non-toxic, physiologically acceptable) salts are preferred, but other salts are also useful, for example when isolating or purifying a compound of the present invention.
[81] Compounds of formula (I) and their intermediates include alkali metals (e.g. sodium, potassium and lithium), alkaline earth metals (e.g. calcium and magnesium), organic bases (e.g. dicyclohexylamine, t-butyl amine, benzatine, N-methyl Salts with -D-glucamide and hydravamin) and amino acids such as arginine, lysine and the like. Such salts can be obtained by reacting these compounds with the desired ions in a medium in which the salt precipitates or in an aqueous medium and then lyophilizing.
[82] When groups such as R ¹ to R ⁴ or R ¹¹ to R ¹⁴ substituents include basic moieties such as amino or substituted amino, the compounds of formula (I) and their intermediates can form salts with various organic and inorganic acids. Such salts include hydrochloric acid, hydrogen bromide, methanesulfonic acid, sulfuric acid, acetic acid, maleic acid, benzenesulfonate, toluenesulfonate and various other sulfonates, nitrates, phosphates, borates, acetates, tartrates, maleates, citrate, Some are formed from succinate, benzoate, ascorbate, salicylate, and the like. Such salts may be formed by reacting these compounds with an equal amount of acid in either the medium in which the salt precipitates or in an aqueous medium and then lyophilizing.
[83] In addition, when groups such as R ¹ to R ⁴ or R ¹¹ to R ¹⁴ substituents contain basic moieties such as amino, amphoteric ions (“salts in molecules”) may be formed.
[84] Certain groups, such as the R ¹ to R ⁴ and R ¹¹ to R ¹⁴ substituents of the compounds of the present invention may contain asymmetric carbon atoms. Therefore, compounds of the present invention, such as compounds of formula (I) and salts thereof, may exist in enantiomeric and diastereoisomeric forms, and racemic mixtures thereof. All fall within the scope of the present invention. In addition, compounds such as compounds of formula (I) and salts thereof may exist as enantiomers even without asymmetric carbon. All such enantiomers are included within the scope of the present invention.
[85] US Pat. Nos. 5,612,359, 5,846,990, and 5,856,507, which describe endothelin antagonists, starting materials, and methods, including compounds of Formula I, which may be prepared herein, are incorporated herein by reference in their entirety. See, in particular, US Pat. No. 5,856,507 for the formation of pinacol esters.
[86] Coupling Compounds of Formula II and Compounds of Formula III
[87] A compound of formula (I) or a salt thereof is prepared by coupling an alkyl boronic acid of formula (II) or a pinacol ester or salt thereof with a halophenyl compound of formula (III) or a salt thereof (preferably when halo is iodo) and then Can be prepared by converting a compound of Formula IV into a compound of Formula V and reacting the compound of Formula V with a compound of Formula VI.
[88] The coupling of a compound of formula (II) (or pinacol ester) with a compound of formula (III) or a salt thereof is a palladium (0) catalyst, preferably palladium acetate / triphenylphosphine or other palladium (II) salt / triphenylphosphine Tetrakisphenylphosphine palladium or tris (dibenzylideneacetone) dipaladium (0) (also referred to herein as "Pd ₂ (dba) ₃ "), and a base containing an alkali metal atom selected from sodium, potassium or lithium , Preferably in the presence of aqueous potassium carbonate or sodium carbonate, to form the compound of formula IV or a salt thereof. A. Suzuki et al., Pure & Applied Chemistry , 63 , 419-422 (1991), incorporated herein by reference; Martin et al ., Acta. Chem. Scand. , 47 , 221 (1993); H. Jendralla et al . Liebig Ann. 1253 (1995).
[89] When the halophenyl compound of formula III is a compound of formula IIIa, the protection of heteroatoms J and K or L may be desirable in any case to promote the coupling reaction. For example, when J and K or L are N, one of these groups may be protected by a suitable protecting group such as t-butoxycarbonyl and the like. Particular R ¹¹ to R ¹⁴ groups can be selected to be compatible with the reaction conditions. In addition, certain R ¹¹ to R ¹⁴ groups may be converted to another R ¹¹ to R ¹⁴ group before or after coupling using any suitable method, such as methods known in the art.
[90] The coupling method is preferably carried out under an atmosphere of argon or nitrogen at a temperature of about 25 ° C. to about 100 ° C. (most preferably about 45 ° C. to about 65 ° C.) and a pressure of about 1 atm. The molar ratio of boronic acid (II) (or pinacol ester) or salt thereof to halophenyl compound (III) or salt thereof is preferably from about 1: 1 to about 1.4: 1. The amount of palladium (0) catalyst and base is selected to catalyze the coupling reaction and is preferably about 2.5 mol% to about 10 mol% and about 2.5 equivalents to about 7 equivalents, respectively. Solvents selected from aqueous or organic liquids such as acetone, ethanol, toluene, tetrahydrofuran, dimethoxyethane and water, or mixtures thereof, preferably mixtures of tetrahydrofuran and dimethoxyethane, are preferably used.
[91] The remaining palladium catalyst is preferably removed by contact with a chelating agent such as trithiocyanuric acid ("TMT") from the compound of formula IV or salts thereof.
[92] Compounds of formula III and salts thereof are commercially available or may be prepared by any suitable method, such as those similar to those described in US Pat. No. 5,846,990. Preferably, the oxazole compound of formula IIIa or a salt thereof is prepared by the novel process for its preparation described herein.
[93] Compounds of formula (II) and salts thereof may be prepared by any suitable method, and preferably by the novel methods of their preparation described herein.
[94] Preparation of Compound of Formula (II)
[95] Boronic acid of formula (II) and salts thereof may be formed by the novel methods provided herein by themselves. According to the present application, boronic acid of formula (II) or a salt thereof is prepared by (a) contacting a compound of formula (VII) or a salt thereof with an alcohol in the presence of an organic base to form a compound of formula (VIII) or a salt thereof; And
[96] (b) lithiating compound (VIII) with an alkyl or aryl lithium compound and contacting the formed lithiation product with trialkylborate and then hydrolyzing to form boronic acid of formula (II) Can be.
[97]
[98]
[99] Where
[100] X is H, Br, Cl or I,
[101] The phenyl group may be further substituted with one or more groups described for example in groups R ¹¹ to R ¹⁴ .
[102] In a preferred embodiment, boronic acid of formula (IIa) or a salt thereof is prepared by (a) contacting a compound of formula (VIIa) or a salt thereof with an alcohol in the presence of an organic base to form a compound of formula (VIIIa); And
[103] (b) lithiating a compound of formula (VIIIa) or a salt thereof with an alkyl or aryl lithium compound and contacting the formed lithiation product with trialkylborate and then hydrolyzing to form boronic acid (IIa) or a salt thereof It can be manufactured by the method.
[104]
[105]
[106] Where
[107] X is H, Br, Cl or I.
[108] The term "leaving group" as used herein refers to any suitable leaving group, such as a halo group, preferably chloro. Any suitable organic base can be used in step (a). Preferred organic bases are amines, in particular tertiary amines (e.g., N-methylmorpholine, especially when X is hydrogen), pyridine or trialkylamines, and aryl or alkyllithium compounds (e.g. n-butyllithium or Phenyllithium).
[109] As mentioned above, compounds of formula (VIIIa) and salts thereof may be prepared by contacting compounds of formula (VIIa) or salts thereof with alcohols. Preferred alcohols are alkyl alcohols such as methanol, ethanol or i-propyl alcohol. The obtained compound of formula VIIIa or a salt thereof is then preferably an alkyl or aryl lithium compound, preferably at about −40 ° C. to about −105 ° C., particularly at about −70 ° C. to about −100 ° C., preferably n- Lithiated with butyl lithium or phenyl lithium (Wherein the phenyl group may be further substituted, for example with one or more groups described in the groups R ¹¹ to R ¹⁴ herein) or salts thereof, preferably To form a compound or a salt thereof. Lithiation occurs selectively at the orthoin position relative to the sulfonyl group of the phenyl ring. The lithiated compound or salt thereof is preferably treated with trialkylborate, preferably triisopropylborate or trimethylborate, at about -40 ° C to about -105 ° C, especially about -70 ° C to about -100 ° C. Boronate in which the phenyl group may be further substituted, for example with one or more groups described in the groups R ¹¹ to R ¹⁴ herein) or salts thereof, preferably The boronate or salt thereof can be obtained and then hydrolyzed to a suitable acid, preferably an aqueous mineral acid such as aqueous sulfuric acid, to form boronic acid of formula (IIa) or a salt thereof. The hydrolysis step to form boronic acid of formula (IIa) or salts thereof is advantageous because boronic acid has improved stability over the boronate esters from which it is obtained. For methods and techniques for starting materials of formula (VIIa) and salts thereof, see European Patent Publication No. 569,193 (1993). Certain of these compounds are also commercially available.
[110] Preparation of Compound of Formula III
[111] Halophenyl compounds of formula III and salts thereof can be prepared by methods analogous to those described in US Pat. No. 5,846,990. Preferred compounds of formula IIIa and salts thereof containing oxazole rings may also be formed by the novel methods provided herein. According to the present application, the oxazole of formula IIIa (1) or a salt thereof is prepared by (a) contacting a phenyl acid halide of formula (IX) or a salt thereof with an amine acetal of formula (X) Forming an amide acetal of XI or a salt thereof;
[112] (b) cyclizing the amide acetal of formula XI or a salt thereof in the presence of Lewis acid and a tertiary amine to form an oxazoline phenyl halide of formula XII or a salt thereof; And
[113] (c) reacting an oxazoline phenyl halide of formula XII with a base to form an oxazole phenyl halide of formula IIIa (1) or a salt thereof.
[114]
[115]
[116]
[117]
[118]
[119] Starting materials Phenic acid halide IX or salts thereof are commercially available or can be readily prepared by those skilled in the art. The halo group of the acid halide moiety is preferably chloro, and the halo group in position paraine to the acid halide moiety is preferably bromo, chloro or iodo, most preferably iodo. Starting materials amine acetal X or salts thereof are also commercially available or can be readily prepared by those skilled in the art. The alkyl group of the acetal moiety is preferably methyl or ethyl, most preferably methyl.
[120] The base used in step (a) may be any suitable base, preferably an alkali metal carbonate, bicarbonate or hydroxide, most preferably such as potassium bicarbonate or methylene chloride in a solvent such as water and / or acetone Potassium carbonate in the solvent.
[121] Cyclic amides may be used to convert amide acetal XI or salts thereof to a Lewis acid (eg, boron trifluoride-etherate, boron tribromide or trimethylsilylchlorosulfo) in an organic solvent such as toluene, dichloromethane or tetrahydrofuran. Nates, most preferably boron trifluoride-etherate and tertiary amines (eg diisopropylethylamine, 4-methylmorpholine, 2,6-lutidine, most preferably diisopropylethyl Amine). The cyclization carried out according to the invention using Lewis acids and tertiary amines does not require the use of high temperatures and does not require the use of undesirable by-products such as Eaton reagents (ie methanesulfonic acid and phosphorus pentoxide) or polyphosphoric acid. It is advantageous in that it does not produce by-products that can occur when used. Cyclization is preferably performed under a temperature of about 0 ° C. to about 50 ° C., a pressure of about 1 atm, and under an argon or nitrogen atmosphere. The base used in step (c) can be any suitable base, preferably an alkoxide base, most preferably potassium or sodium tert-butoxide.
[122] Formation of compounds of formula (I) by conversion of compounds of formula (IV) to compounds of formula (V) and coupling with compounds of formula (VI)
[123] Compounds of formula (I), for example compounds of formula (Ia) and salts thereof, can be formed by the novel methods provided herein.
[124] The compound of formula IV is preferably a compound of formula V by contact with any suitable chlorinating agent, for example dimethylchloromethyleneammonium chloride, phosphorus pentachloride, oxalyl chloride or thionyl chloride, in a solvent such as toluene Can be converted to
[125] Compounds of formula (I) can be prepared by contacting a compound of formula (V) with a compound of formula (VI) in the presence of a base, preferably sodium hydride or alkoxide base, most preferably sodium or potassium tert-butoxide. In the case of using sodium t-butoxide, the reaction is preferably carried out at room temperature or lower, and when potassium t-butoxide is used the use of lower temperatures (eg -78 ° C) is preferred. The compound of formula VI may be premixed with a base to form an anion prior to contact with the compound of formula V.
[126] Crystallization provides a suitable crystalline form of a compound of formula (I) (in particular formula (Ia)) or a salt thereof as a result of the coupling of a compound of formula (V) or a salt thereof with a compound of formula (VI). Most preferably, crystallization is performed by the method of the examples herein.
[127] Preferred Compound
[128] The compounds used in or prepared by the process of the invention preferably have one or more, preferably all of the following substituents.
[129] X is O and N is Y;
[130] The ring containing K, L and J is 2-oxazole;
[131] p is 0;
[132] R ¹ and R ² are each independently hydrogen, alkyl, alkoxy, aryl, hydroxyalkyl, -CO ₂ R ⁵ or -Z ⁴ -NR ⁶ R ⁷ , most preferably lower alkyl or hydrogen;
[133] R ³ and R ⁴ are each independently alkyl, most preferably lower alkyl, especially methyl;
[134] R ¹¹ , R ¹² , R ¹³ and R ¹⁴ are each independently hydrogen, hydroxy, amino, heterocyclo, alkenyl, alkoxy, carboxamide or substituted lower alkyl, most preferably R ¹² to R ¹⁴ are Hydrogen, R ¹¹ is hydrogen, hydroxy, amino, heterocyclo, alkenyl, alkoxy, carboxamide or substituted lower alkyl such as —CH ₂ —N (CH ₃ ) —C (O) —CH ₂ — C (CH ₃ ) ₃ ).
[135] Particularly important compounds of formula I include N- (3,4-dimethyl-5-isoxazolyl) -4 '-(2-oxazolyl)-[1,1'-biphenyl] -2-sulfonamide and its Salts, and N-[[2 '-[[4,5-dimethyl-3-isoxazolyl) amino] sulfonyl] -4- (2-oxazolyl) [1,1'-biphenyl] -2- Il] methyl] -N, 3,3-trimethylbutanamide and salts thereof.
[136] Usefulness of Compounds of Formula (I) and Salts thereof as Endothelin Antagonists
[137] Compounds of formula (I) and salts thereof are antagonists of ET-1, ET-2 and / or ET-3, which are associated with elevated ET levels (eg dialysis, trauma and surgery) and all endothelin-dependent disorders. It is useful for treatment. Therefore, they are useful as antihypertensive agents. By administering a composition having one (or mixed) compound of the invention, the blood pressure of a hypertensive mammalian (eg human) host is reduced. They are also useful for hypertension and coma due to pregnancy (automatism and eclampsia), acute portal hypertension and hypertension following erythropoietin treatment.
[138] The compounds of the present invention also provide for acute and chronic renal failure, glomerular damage, kidney damage caused by old age or related to dialysis, neurosis (particularly hypertensive neurosis), nephrotoxicity (neotoxicity related to imaging and contrast agents and nephrotoxicity related to cyclosporin). And renal ischemia, primary bladder ureter reflux, glomerulosclerosis, and the like, and are useful for the treatment of disorders related to cellular function of the kidney, glomeruli and glomerular epilepsy. The compounds of the present invention may also be useful for the treatment of disorders related to lateral endocrine and endocrine function.
[139] The compounds of the present invention are also useful for the treatment of endotoxin or endotoxin shock, and hemorrhagic shock.
[140] The compounds of the present invention are also useful for hypoxia and ischemic diseases, and for example, anti-ischemic agents for the treatment of heart, kidney and cerebral ischemia and reperfusion (e.g. after cardiopulmonary bypass surgery), coronary and cerebral vasospasm, etc. Useful as
[141] In addition, the compounds of the present invention also include antiarrhythmic agents; Antianginal agents; Anti defibrillation agents; Anti-asthmatic agents; Anti-atherogenic and anti-arteriosclerosis agents; Heart attack additives for cardiopulmonary bypass; Thrombolytic therapy aids; And branch agents. Compounds of the invention are also useful for the treatment of myocardial infarction; Treatment of peripheral vascular diseases (eg, Raynaud's disease and Takaya's disease); Treatment of cardiac hypertrophy (eg, hypertrophic cardiomyopathy); Treatment of primary pulmonary hypertension (eg, plexus-derived, embolic) and pulmonary hypertension or other trauma following heart failure, radiation and chemotherapy injury in adults and newborns; Treatment of central nervous system vascular disorders such as seizures, migraine and subarachnoid hemorrhage; Treatment of central nervous system behavioral disorders; Treatment of gastrointestinal disorders such as ulcerative colitis, Crohn's disease, gastric mucosal injury, ulcers and ischemic bowel disease; Treatment of gallbladder or biliary tract diseases such as cholangitis; Treatment of pancreatitis; Regulation of cell growth; Treatment of benign prostatic hyperplasia; Restenosis after angioplasty or after any process, including transplantation; Treatment of congestive heart failure, including inhibition of fibrosis; Inhibition of left ventricular dilatation, remodeling and dysfunction; And hepatotoxicity and sudden death. The compounds of the present invention may be used for the treatment of sickle cell disease, including the onset and / or progression of pain development of sickle cell disease; Treatment of adverse consequences of ET-producing tumors, such as hypertension due to pericarcinoma; Treatment of early and progressive liver diseases and injuries, including incidental complications (eg, hepatotoxicity, fibrosis and cirrhosis); Treatment of spasms of the urinary tract and / or bladder; Treatment of hepatic syndrome; Treatment of immune diseases including vasculitis, such as lupus, systemic sclerosis, mixed Hanglobulinemia; And fibrosis associated with renal failure and hepatotoxicity. Compounds of the invention include metabolic and neurological disorders; cancer; Insulin-dependent and insulin-independent diabetes mellitus; Neuropathy; Retinopathy; Maternal respiratory distress syndrome; Irregular menstruation; epilepsy; Hemorrhagic and ischemic attacks; Bone remodeling; psoriasis; And chronic inflammatory diseases such as rheumatoid arthritis, osteoarthritis, sarcoidosis and eczema dermatitis (all types of dermatitis). The compounds of formula (I) are preferably useful for congestive heart failure and male erectile dysfunction.
[142] Compounds of formula (I) and salts thereof also include endothelin converting enzyme (ECE) inhibitors such as phosphoramidone; Thromboxane receptor antagonists; Potassium channel openings; Thrombin inhibitors (eg, hirudin and the like); Growth factor inhibitors such as modulators of PDGF activity; Platelet activating factor (PAF) antagonists; Angiotensin II (AII) receptor antagonists; Renin inhibitors; Angiotensin converting enzyme (ACE) inhibitors such as captopril, jofenopril, posinopril, seranapril, alacepril, enalapril, delapril, fentopril, quinapril, ramipril, risinopril and these Salts of compounds; Neutral endopeptidase (NEP) inhibitors; Dual NEP-ACE inhibitors; HMG CoA reductase inhibitors such as pravastatin and mebacor; Squalene synthetase inhibitors; Bile acid sequestrants such as questran; Calcium channel blocker; Potassium channel actives; Beta-adrenergic agents; Antiarrhythmic agents; Diuretics such as chlorothiazide, hydrochlorothiazide, flumetiazide, hydroflumetiazide, bendroflumetiazide, methylchlorothiazide, trichloromethiazide, polythiazide or benzothiazide and Ethacrynic acid, tricrinafen, chlortalidone, furosemide, musolemin, bumetanide, triamterene, amylolide and spironolactone and salts of these compounds; And thrombolytic agents, such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase and anisolate plasminogen streptokinase activator complex (APSAC). Can be. If formulated at fixed dosages, such mixed products utilize the compounds of the invention within the dosage ranges described below and other pharmaceutically active agents within the applied dosage ranges. The compounds of the present invention may also be formulated with or useful with antifungal and immunosuppressive agents, such as amphotericin B, cyclosporin, and the like, to counteract glomerular contraction and nephrotoxicity according to these compounds. The compounds of the present invention can also be used with hemodialysis.
[143] The compounds of the present invention are used in various mammalian species known to be susceptible to such diseases, such as humans, from about 0.1 to about 100 mg / kg, preferably from about 0.2 to about 50 mg / kg and more preferably from about 0.5 to about It may be administered orally or parenterally once a day or divided into 2 to 4 times in an effective amount within the dosage range of 25 mg / kg (or about 1 to about 2500 mg, preferably about 5 to about 2000 mg).
[144] The active substance is a composition such as a tablet, capsule, solution or suspension containing from about 5 to about 500 mg of a compound or formula of formula I per unit dose or topical form for wound healing (0.01 to 5% by weight of the compound of formula I, 1 to 5 times a day). They are conventionally combined with physiologically acceptable vehicles or carriers, excipients, binders, preservatives, stabilizers, fragrances and the like or with topical carriers such as plastibases (mineral oil gelled with polyethylene) required in acceptable pharmaceutical practice. It can be formulated as.
[145] The compounds of the present invention may also be administered topically to treat peripheral vascular disease and may be formulated as a cream or ointment by themselves.
[146] The compounds of formula (I) can also be formulated in compositions such as sterile solutions or suspensions for parenteral administration. About 0.1 to 500 mg of a compound of Formula (I) is combined with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer and the like in unit dosage form as required by acceptable pharmaceutical practice. The amount of active substance in these compositions or formulations is such that a suitable dosage within the specified range is obtained.
[147] The invention will now be further described by the following examples which illustrate preferred embodiments of the invention.
[148] Example 1
[149] N- (2,2-dimethoxyethyl) -4-iodobenzamide (amide acetal)
[150]
[151] A solution of 4-iodobenzoyl chloride (100 g, 375.6 mmol) in 300 ml of acetone was added with 270 ml of acetone and aminoacetyl dimethylacetal (41.4 g, 1.05 equiv) and potassium hydrogen carbonate (39.5 g, 1.05 equiv) in 450 ml of water. Was added to the solution. After the reaction was completed, acetone was removed at 35 ° C. or lower to induce crystallization. The crystal slurry was filtered, washed and dried under vacuum at below 50 ° C. to give 120 g (95% M%, HPLC area% 96) of the title compound.
[152] Example 2
[153] 2- (4-iodophenyl) oxazole (iodooxazole)
[154]
[155] Under an inert atmosphere, methanesulfonic acid (141 g, 1.46 mol) was added to a mixture of amide acetal (25 g, 74.6 mmol) and phosphorus pentoxide (25 g, 176 mmol). The reaction mixture was heated at 140 ° C. for about 12 hours. The reaction mixture was cooled to 0 ° C and 150 mL of water was added while maintaining the reaction temperature below 40 ° C. The pH of the reaction mixture was adjusted to 12.5-13 with 50% sodium hydroxide and the reaction mixture was heated to about 45 ° C. to hydrolyze the carcinogenic byproduct methyl methanesulfonate. The reaction mixture was cooled to ambient temperature and 100 mL of tetrahydrofuran was added. The pH was adjusted to 5 with concentrated hydrochloric acid and the layers separated. The spent aqueous phase was extracted twice with 100 ml of acetone. The rich organic extracts were combined and crystallization was carried out by adding 200 ml of water. The crystal slurry was filtered, washed and dried under vacuum at below 50 ° C. to give 17 g (84 M%, HPLC area%> 99) of the title compound.
[156] Alternatively, polyphosphoric acid can be used as the cyclizing agent.
[157] Another method of preparation of the title compound
[158] Under an inert atmosphere, a solution of boron trifluoride etherate (88 mL, 0.72 mol) in amide acetal (30 g, 0.089 mol) and diisopropylethylamine (124.8 mL, 0.72 mol) in 200 mL of dichloromethane at below 10 ° C Dropped in The reaction mixture was again heated to about 40 ° C. for 3-6 hours. The reaction mixture was cooled below −10 ° C. and a solution of potassium tert-butoxide (110.5 g, 0.98 mol) in tetrahydrofuran (550 mL) was added. The reaction mixture was heated at about 40 ° C. for 3-6 hours. The reaction mixture was cooled to room temperature and 300 mL of water was added. The pH of the biphasic mixture was adjusted to about 7 with concentrated hydrochloric acid. The layers were separated. The rich organic layer was concentrated to dryness. The crude product was dissolved in 300 ml of acetone and filtered to remove insolubles. About 200 ml of water was added to the rich acetone solution to effect crystallization. The crystal slurry was filtered, washed and dried under vacuum at below 50 ° C. to give 17 g (70 M%, HPLC area%> 99) of the title compound.
[159] Example 3
[160] 2-bromobenzenesulfonic acid, 1-methylethyl ester
[161]
[162] 2-bromobenzenesulfonyl chloride (50 g, 0.19 mol) was suspended in 2-propanol (45 mL, 3 equiv) and the slurry was cooled to below 10 ° C. Pyridine (32 mL, 2 equiv) was added in small portions to keep the reaction temperature below 10 ° C. After the reaction was completed (about 3 hours), 11 ml of glacial acetic acid was added followed by 250 ml of methyl tert-butyl ether (MTBE). The layers were separated and the rich organic layer was washed successively with 125 mL of 1N aqueous hydrochloric acid and 150 mL of saturated sodium bicarbonate. The rich MTBE solution was solvent exchanged with hexane (ie, distillation of MTBE simultaneously with addition of hexane) to induce crystallization. The crystal slurry was filtered, washed and dried under vacuum at 25 ° C. to give 48 g (87 M%, HPLC area%> 99) of the title compound.
[163] Example 4
[164] Benzenesulfonic acid, 1-methylethyl ester
[165]
[166] Benzenesulfonyl chloride (50 g, 283 mmol) was added to a solution of 4-methylmorpholine (57 g, 2 equiv) and isopropyl alcohol (66 g, 3.9 equiv). After the reaction was completed (about 3 hours), 250 ml of methyl tert-butyl ether (MTBE) and 60 ml of 3M sulfuric acid were added. The rich MTBE layer was washed with aqueous sodium chloride solution. The rich MTBE solution was solvent exchanged with tetrahydrofuran solution. A rich tetrahydrofuran solution containing 56 g (96 M%, HPLC area% 97) of the title compound was used as such in the next step (Example 5).
[167] Example 5
[168] 2-boronbenzenesulfonic acid, 1-methylethyl ester
[169]
[170] Triisopropylborate (84 mL, 1.82 equiv) was added to a solution of the product of Example 3 (56 g, 200 mmol) in 280 mL of THF, and the reaction mixture was cooled to below -65 ° C. To the cooled solution, n-butyllithium (144 mL, 0.9 equiv, 1.07 M in hexane) was added slowly to maintain the temperature below -65 ° C. The reaction mixture was stirred for at least 0.5 h and then quenched with 1 M sulfuric acid (200 mL). The reaction mixture was warmed to about 20 ° C. The layers were separated and the rich organic layer containing 35 g (92 M%, HPLC area% 98) of the title compound was used as such in the next step (Example 6).
[171] Another method of preparation of the title compound
[172] The THF solution of Example 4 containing 40 g (200 mmol) of product was cooled to below -65 ° C. To the cooled solution, n-butyllithium (144 mL, 0.9 equiv, 1.07 M in hexane) was added slowly to maintain the temperature below -65 ° C. The reaction mixture was stirred for at least 0.5 hours and the temperature was kept below -65 ° C. with the addition of triisopropylborate (84 mL, 1.82 equiv). The reaction mixture was quenched with 1M sulfuric acid (200 mL) and the reaction mixture was warmed to about 20 ° C. The layers were separated and the rich organic layer containing 33 g (87 M%, HPLC area% 94) of the title compound was used as such in the next step (Example 6).
[173] Example 6
[174] 4 '-(2-oxazolyl) [1,1'-biphenyl] -2-sulfonic acid, sodium salt
[175]
[176] The THF-hexane-MTBE solution containing 23 g (93.3 mmol) of the title compound of Example 5 was concentrated to a concentration of about 7 mL / g. A portion of this solution containing about 4.7 g (19 mmol, 0.26 equiv) was added to a solution of 20 g (75 mmol) of the title compound of Example 2 dissolved in 100 mL of degassed tetrahydrofuran. To this solution, tris (dibenzylidene acetone) dipalladium (0) (0.5 g, 0.6 M%) and degassed aqueous sodium carbonate solution (300 mL, 3 equiv) were added. The reaction mixture was heated to about 50 ° C. to initiate the coupling reaction. During the reaction, a rich organic concentrate containing Pd ₂ (dba) ₃ (0.5 g / 1 addition) and the title compound of Example 5 (4.7 g, 0.26 equiv / 1 addition) was added to all iodooxazoles. Add in several portions until consumed. The reaction mixture was further heated at about 55 ° C. for an additional 4 hours. The reaction mixture was filtered and washed with methyl tert-butyl ether. The pH of the product-rich aqueous solution was adjusted to about 4, treated with trithiocyanuric acid (1 g) and filtered to remove by-products containing Pd. The pH of the product-rich aqueous solution was adjusted to about 7 and saturated with solid NaCl (118 g) to induce crystallization of the product. The salted product was dried under about 70 ° C. under vacuum. For recrystallization, the dried product was dissolved in 350 ml of 190 standard ethanol at about 75 ° C. The solution was filtered, concentrated to about 100 mL and cooled to about 30 ° C. to initiate crystallization. Approximately 200 ml of methyl tert-butyl ether was added to maximize yield. The crystal slurry was filtered, washed and dried in vacuo at below 70 ° C. to give 19 g (74 M%, HPLC area% 100) of the title compound.
[177] Example 7
[178] N- (3,4-dimethyl-5-isoxazolyl) -4 '-(2-oxazolyl)-[1,1'-biphenyl] -2-sulfonamide
[179]
[180] About 15.5 g (47.9 mmol) of the title compound of Example 6 were suspended in 200 mL of toluene and Vilsmeier reagent (9 g, 71.8 mmol) was added at room temperature. The mixture was stirred until the chlorination reaction was complete (about 3 hours). The reaction mixture was quenched with 50 mL of water and the pH was adjusted to 7-10 with 10N NaOH. The layers were separated and azeotropically water was removed from the rich toluene solution to bring the moisture content below 0.05%. This rich toluene solution was added to a solution of 5-amino-3,4-dimethylisoxazole (6.1 g, 54.4 mmol) in 90 mL of tetrahydrofuran. The reaction mixture was cooled to −15 ° C. and a slurry of sodium t-butoxide (10 g, 104.3 mmol) in 70 ml tetrahydrofuran was added. After the coupling reaction was completed, the mixture was quenched with 100 mL of water and then warmed to about 50 ° C. to obtain two transparent phases. The spent organic layer was extracted with water (50 mL). To the mixed rich aqueous solution, 85 ml of 190 standard ethanol and 15 ml of tetrahydrofuran were added. The pH was adjusted to about 2 with concentrated HCl to precipitate the product. The resulting slurry was heated to about 75 ° C. to dissolve the product. The product crystallized while slowly cooling to room temperature. Additional water (120 mL) was added to maximize yield. The crystal slurry was filtered, washed and dried under vacuum at below 60 ° C. to give 16 g (85 M%, HPLC area% 99.6) of the title compound.

权利要求:
Claims (31)
[1" claim-type="Currently amended] (a) in the presence of a palladium (0) catalyst and a base containing an alkali metal atom selected from sodium, potassium or lithium, a boronic acid of formula (II) or a pinacol ester or salt thereof is substituted with a halophenyl compound of formula (III) Contacting a salt to form a compound of formula IV or a salt thereof, and converting the compound of formula IV or a salt thereof to a compound of formula V or a salt thereof with a chlorinating agent; And
(b) in the presence of a base, coupling the compound of formula V or a salt thereof with a compound of formula VI to form a compound of formula I or a salt thereof
A process for preparing biphenyl sulfonamides of the formula (I), enantiomers and diastereomers thereof, and salts, comprising:
<Formula I>

Where
The phenyl ring of the biphenyl group may be independently unsubstituted or substituted with one or more substituents;
One of X and Y is N and the other is O;
R ³ and R ⁴ are each directly bonded to the ring carbon, and each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) -C (O) H or -C (O) R ⁵ ; (h) -CO ₂ H or -CO ₂ R ⁵ ; (i) -Z ⁴ -NR ⁶ R ⁷ ; (j) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ ; or
(k) R ³ and R ⁴ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ so that together with the carbon atoms to which they are attached a 4 to 8 membered saturated, unsaturated or aromatic ring Can complete;
R ⁵ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl which may be substituted with Z ¹ , Z ² and Z ³ ;
R ⁶ , R ⁷ , R ⁸ , R ⁹ and R ¹⁰ are each independently (a) hydrogen; Or (b) alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl which may be substituted with Z ¹ , Z ² and Z ³ ; or
R ⁶ and R ⁷ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ to complete a 3-8 membered saturated or unsaturated ring with the nitrogen atom to which they are attached ; Or any two of R ⁸ , R ⁹ and R ¹⁰ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ to form a three to eight membered saturation together with the atoms to which they are attached; Or complete the unsaturated ring;
Z ¹ , Z ² and Z ³ are each independently (a) hydrogen; (b) halo; (c) hydroxy; (d) alkyl; (e) alkenyl; (f) aryl; (g) aralkyl; (h) alkoxy; (i) aryloxy; (j) aralkoxy; (k) heterocycles, substituted heterocycles or heterocyclooxy; (l) -SH, -S (O) _n Z ⁶ , -S (O) _m -OH, -S (O) _m -OZ ⁶ , -OS (O) _m -OZ ⁶ , -OS (O) _m OH or —OS (O) _m —OZ ⁶ ; (m) oxo; (n) nitro; (o) cyano; (p) —C (O) H or —C (O) Z ⁶ ; (q) -CO ₂ H or -CO ₂ Z ⁶ ; (r) -Z ⁴ -NZ ⁷ Z ⁸ ; (s) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -H; (t) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -Z ⁶ ; Or (u) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -NZ ⁷ Z ⁸ ;
Z ⁴ and Z ⁵ are each independently (a) a single bond; (b) Z ⁹ -S (O) _n -Z ^10- ; (c) Z ⁹ -C (O) -Z ^10- ; (d) Z ⁹ -C (S) -Z ^10- ; (e) Z ⁹ -OZ ^10- ; (f) Z ⁹ -SZ ^10- ; (g) Z ⁹ -OC (O) -Z ^10- ; Or (h) Z ⁹ -C (O) -OZ ^10- ;
Z ⁶ is alkyl; Alkyl substituted with 1 to 3 groups selected from halogen, aryl, aryloxy and alkoxy; Alkenyl; Alkynyl; Cycloalkyl; Cycloalkyl substituted with 1 to 3 groups selected from alkyl, aryl, alkenyl and alkoxyaryl; Cycloalkyl to which benzene ring is fused; Aryloxy substituted with one or two halogens; Cycloalkylalkyl; Cycloalkenyl; Cycloalkenylalkyl; Aryl; Aryl substituted with 1 to 4 groups or methylenedioxy selected from alkyl, dialkylamino, cyano, halogen, trihaloalkyl, alkoxy and trihaloalkoxy; Or a hetero ring or a substituted hetero ring;
Z ⁷ and Z ⁸ are each independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl, or Z ⁷ and Z ⁸ together form alkylene or alkenylene to which they are attached Completing a 3-8 membered saturated or unsaturated ring with a nitrogen atom;
Z ⁹ and Z ¹⁰ are each independently a single bond, alkylene, alkenylene or alkynylene;
Z ¹¹ is (a) hydrogen; Or (b) alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl substituted with alkyl, 1, 2 or 3 halogen; or
Any two of Z ⁷ , Z ⁸ and Z ¹¹ together form an alkylene or alkenylene to complete a three to eight membered saturated or unsaturated ring with the atoms to which they are attached;
m is each independently 1 or 2;
n is 0, 1 or 2 each independently.
<Formula II>

Where
R is an alkyl group,
The phenyl ring may be further substituted.
<Formula III>

Where
The phenyl ring may be further substituted.
<Formula IV>

<Formula V>

Where
The phenyl ring of the biphenyl group of formula IV or formula V may be independently unsubstituted or substituted with one or more substituents;
M is sodium, potassium or lithium.
<Formula VI>

In which R is₃ And R₄Is the same as above.
[2" claim-type="Currently amended] The boronic acid of formula (IIa) or a salt thereof according to claim 1, wherein (a) in the presence of a palladium (0) catalyst and a base containing an alkali metal atom selected from sodium, potassium or lithium Or contacting with a salt thereof to form a compound of formula IVa or a salt thereof, and converting the compound of formula IVa to a compound of formula Va with a chlorinating agent; And
(b) coupling a compound of formula Va or a salt thereof with a compound of formula VI in the presence of a base to form a compound of formula la or a salt thereof
Wherein the compound of formula (I) is a compound of formula (Ia) or a salt thereof.
<Formula Ia>

<Formula IIa>

<Formula IIIa>

<Formula IVa>

<Formula Va>

Where
R ¹ and R ² are each directly bonded to a ring carbon, each independently selected from the groups (a) to (j) cited for R ³ and R ⁴ in claim 1;
R ¹¹ , R ¹² , R ¹³ and R ¹⁴ are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) heterocycles, substituted heterocycles or heterocyclooxy; (d) halo; (e) hydroxyl; (f) cyano; (g) nitro; (h) —C (O) H or —C (O) R ⁵ ; (i) -CO ₂ H or -CO ₂ R ⁵ ; (j) -SH, -S (O) _n R ⁵ , -S (O) _m -OH, -S (O) _m -OR ⁵ , -OS (O) _m -OR ⁵ , -OS (O) _m OH or —OS (O) _m —OR ⁵ ; (k) -Z ⁴ -NR ⁶ R ⁷ ; Or (l) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ ;
J is O, S, N or NR ¹⁵ ;
K and L are N or C, provided that at least one of K or L is C;
R ¹⁵ is hydrogen, alkyl, hydroxyethoxy methyl or methoxyethoxy methyl;
p is 0 or an integer of 1 or 2.
R is an alkyl group,
M is lithium, sodium or potassium.
[3" claim-type="Currently amended] The process of claim 2 wherein the palladium (0) catalyst is a palladium (II) salt and triphenylphosphine.
[4" claim-type="Currently amended] The process of claim 3 wherein the palladium (II) salt is palladium acetate.
[5" claim-type="Currently amended] 3. The process of claim 2 wherein the palladium catalyst is tris (dibenzylideneacetone) dipalladium (0).
[6" claim-type="Currently amended] The process of claim 2 wherein the base in step (a) is aqueous potassium carbonate or sodium carbonate.
[7" claim-type="Currently amended] The method of claim 2, wherein the halo group in the compound of formula IIIa or a salt thereof is bromo or iodo.
[8" claim-type="Currently amended] The process of claim 2, wherein the compound of formula la or a salt thereof is crystallized from solution following step (b).
[9" claim-type="Currently amended] The method of claim 2, wherein the remaining palladium is removed using a chelating agent after contact of the compound of Formula IIa with the compound of Formula IIIa.
[10" claim-type="Currently amended] The method of claim 2 wherein the chlorinating agent is a Vilsmeier reagent, thionyl chloride, oxalyl chloride or phosphorus oxychloride.
[11" claim-type="Currently amended] The process of claim 2 wherein the base in step (b) is sodium hydride, potassium tert-butoxide or sodium tert-butoxide.
[12" claim-type="Currently amended] The compound of formula Ia according to claim 2, wherein the compound of formula Ia is N- (3,4-dimethyl-5-isoxazolyl) -4 '-(2-oxazolyl)-[1,1'-biphenyl] -2-sulphone Amide or a salt thereof.
[13" claim-type="Currently amended] 3. A compound of formula Ia according to claim 2 wherein the compound of formula la is N-[[2 '-[[(4,5-dimethyl-3-isoxazolyl) amino] sulfonyl] -4- (2-oxazolyl) [1, 1'-biphenyl] -2-yl] methyl] -N, 3,3-trimethylbutanamide or a salt thereof.
[14" claim-type="Currently amended] (a) contacting a compound of formula VII or a salt thereof with an alcohol in the presence of an organic base to form a compound of formula VIII or a salt thereof; And
(b) lithiating compound VIII with an alkyl or aryl lithium compound and contacting the formed lithiation product with trialkylborate followed by hydrolysis
A method of preparing boronic acid or a salt thereof, comprising:
<Formula II>

Where
The phenyl ring may be further substituted.
<Formula VII>

Where
X is H, Cl, Br or I,
The phenyl group may be further substituted.
<Formula VIII>

Where
R is an alkyl group.
[15" claim-type="Currently amended] The method of claim 14, further comprising: (a) contacting a compound of formula (VIIa) or a salt thereof with an alcohol in the presence of an organic base to form a compound of formula (VIIIa) or a salt thereof; And
(b) lithiating the compound of formula VIIIa or a salt thereof with an alkyl or aryl lithium compound and contacting the formed lithiation product with trialkylborate and then hydrolyzing to form boronic acid of formula IIa or a salt thereof
A method for preparing boronic acid or a salt thereof, comprising:
<VIIa>

<Formula VIIIa>

<Formula IIa>

Where
X is H, Cl, Br or I,
R ¹³ and R ¹⁴ are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) heterocycles, substituted heterocycles or heterocyclooxy; (d) halo; (e) hydroxyl; (f) cyano; (g) nitro; (h) —C (O) H or —C (O) R ⁵ ; (i) -CO ₂ H or -CO ₂ R ⁵ ; (j) -SH, -S (O) _n R ⁵ , -S (O) _m -OH, -S (O) _m -OR ⁵ , -OS (O) _m -OR ⁵ , -OS (O) _m OH or —OS (O) _m —OR ⁵ ; (k) -Z ⁴ -NR ⁶ R ⁷ ; Or (l) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ .
[16" claim-type="Currently amended] The method of claim 15, wherein X of the compound of formula (VIIa) or a salt thereof is bromo or hydrogen.
[17" claim-type="Currently amended] The method of claim 15, wherein the leaving group is halo.
[18" claim-type="Currently amended] 18. The method of claim 17, wherein the leaving group is chloro.
[19" claim-type="Currently amended] The process of claim 15 wherein the organic base in step (a) is a tertiary amine.
[20" claim-type="Currently amended] The process of claim 15 wherein the organic base in step (a) is an alkyl or aryl lithium compound.
[21" claim-type="Currently amended] The method of claim 15, wherein the alcohol is isopropyl alcohol.
[22" claim-type="Currently amended] The method of claim 15, wherein the alkyl or aryl lithium compound in step (b) is n-butyl lithium or phenyl lithium.
[23" claim-type="Currently amended] The method of claim 15, wherein the trialkylborate is triisopropylborate or trimethylborate.
[24" claim-type="Currently amended] (a) contacting a phenyl acid halide of formula (IX) or a salt thereof in the presence of a base and a solvent with an amine acetal of formula (X) or a salt thereof to form an amide acetal of formula (XI) or a salt thereof;
(b) cyclizing the amide acetal of formula XI or a salt thereof in the presence of Lewis acid and a tertiary amine to form an oxazoline phenyl halide of formula XII or a salt thereof; And
(c) reacting an oxazoline phenyl halide of formula XII with a base to form an oxazole phenyl halide of formula IIIa (1) or a salt thereof
A method of preparing an oxazole phenyl halide of formula IIIa (1) or a salt thereof, comprising:
<Formula IIIa (1)>

<Formula IX>

<Formula X>

<Formula XI>

<Formula XII>

Where
R ¹ and R ² are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) -C (O) H or -C (O) R ⁵ ; (h) -CO ₂ H or -CO ₂ R ⁵ ; (i) -Z ⁴ -NR ⁶ R ⁷ ; Or (j) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ ;
R ⁵ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl which may be substituted with Z ¹ , Z ² and Z ³ ;
R ⁶ , R ⁷ , R ⁸ , R ⁹ and R ¹⁰ are each independently (a) hydrogen; Or (b) alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl which may be substituted with Z ¹ , Z ² and Z ³ ; or
R ⁶ and R ⁷ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ to complete a 3-8 membered saturated or unsaturated ring with the nitrogen atom to which they are attached ; Or any two of R ⁸ , R ⁹ and R ¹⁰ together form an alkylene or alkenylene which may be substituted with Z ¹ , Z ² and Z ³ , together with the atoms to which they are attached Complete saturated or unsaturated rings;
R ¹¹ and R ¹² are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or which may be substituted by Z ¹ , Z ² and Z ³ Aralkoxy; (c) heterocycles, substituted heterocycles or heterocyclooxy; (d) halo; (e) hydroxyl; (f) cyano; (g) nitro; (h) —C (O) H or —C (O) R ⁵ ; (i) -CO ₂ H or -CO ₂ R ⁵ ; (j) -SH, -S (O) _n Z ⁶ , -S (O) _m -OH, -S (O) _m -OZ ⁵ , -OS (O) _m -OZ ⁵ , -OS (O) _m OH or —OS (O) _m —OZ ⁵ ; (k) -Z ⁴ -NR ⁶ R ⁷ ; Or (l) -Z ⁴ -N (R ¹⁰ ) -Z ⁵ -NR ⁸ R ⁹ ;
Z ¹ , Z ² and Z ³ are each independently
(a) hydrogen; (b) halo; (c) hydroxy; (d) alkyl; (e) alkenyl; (f) aryl; (g) aralkyl; (h) alkoxy; (i) aryloxy; (j) aralkoxy; (k) heterocycles, substituted heterocycles or heterocyclooxy; (l) -SH, -S (O) _n Z ⁶ , -S (O) _m -OH, -S (O) _m -OZ ⁶ , -OS (O) _m -Z ⁶ , -OS (O) _m OH or —OS (O) _m —OZ ⁶ ; (m) oxo; (n) nitro; (o) cyano; (p) —C (O) H or —C (O) Z ⁶ ; (q) -CO ₂ H or -CO ₂ Z ⁶ ; (r) -Z ⁴ -NZ ⁷ Z ⁸ ; (s) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -H; (t) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -Z ⁶ ; Or (u) -Z ⁴ -N (Z ¹¹ ) -Z ⁵ -NZ ⁷ Z ⁸ ;
Z ⁴ and Z ⁵ are each independently (a) a single bond; (b) Z ⁹ -S (O) _n -Z ^10- ; (c) Z ⁹ -C (O) -Z ^10- ; (d) Z ⁹ -C (S) -Z ^10- ; (e) Z ⁹ -OZ ^10- ; (f) Z ⁹ -SZ ^10- ; (g) Z ⁹ -OC (O) -Z ^10- ; Or (h) Z ⁹ -C (O) -OZ ^10- ;
Z ⁶ is alkyl; Alkyl substituted with one to three groups selected from halogen, aryl, aryloxy and alkoxy; Alkenyl; Alkynyl; Cycloalkyl; Cycloalkyl substituted with 1 to 3 groups selected from alkyl, aryl, alkenyl and alkoxyaryl; Cycloalkyl to which benzene ring is fused; Aryloxy substituted with one or two halogens; Cycloalkylalkyl; Cycloalkenyl; Cycloalkenylalkyl; Aryl; Aryl substituted with 1 to 4 groups or methylenedioxy selected from alkyl, dialkylamino, cyano, halogen, trihaloalkyl, alkoxy and trihaloalkoxy; Or a hetero ring or a substituted hetero ring;
Z ⁷ and Z ⁸ are each independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl, or Z ⁷ and Z ⁸ together form alkylene or alkenylene to which they are attached Completing a 3-8 membered saturated or unsaturated ring with a nitrogen atom;
Z ⁹ and Z ¹⁰ are each independently a single bond, alkylene, alkenylene or alkynylene;
Z ¹¹ is (a) hydrogen; Or (b) alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl or aralkyl substituted with alkyl, 1, 2 or 3 halogen; or
Any two of Z ⁷ , Z ⁸ and Z ¹¹ together form an alkylene or alkenylene to complete a three to eight membered saturated or unsaturated ring with the atoms to which they are attached;
m is each independently 1 or 2;
n is 0, 1 or 2 each independently.
[25" claim-type="Currently amended] The method of claim 24 wherein the halo group of the acid halide moiety in formula IX is chloro and the halo group in the para position relative to the acid halide moiety is chloro, bromo or iodo.
[26" claim-type="Currently amended] The method of claim 24, wherein the alkyl group of the acetal moiety is methyl or ethyl.
[27" claim-type="Currently amended] The method of claim 24, wherein the base used in step (a) is an alkali metal bicarbonate, carbonate or hydroxide.
[28" claim-type="Currently amended] The method of claim 24, wherein the Lewis acid is boron trifluoride-etherate and the tertiary amine is diisopropylethylamine.
[29" claim-type="Currently amended] The method of claim 24, wherein the base used in step (c) is potassium tert-butoxide or sodium tert-butoxide.
[30" claim-type="Currently amended] 25. The process of claim 24, wherein the oxazole of formula IIIa (1) or a salt thereof is used in the preparation of a compound of formula la or a salt thereof as described in claim 2.
[31" claim-type="Currently amended] The compound of claim 24, wherein the oxazole phenyl halide of formula IIIa (1) or a salt thereof is 2- (4-iodophenyl) oxazole, the phenyl acid halide of formula IX or a salt thereof is 4-iodobenzoyl chloride, The amine acetal of formula (X) or a salt thereof is aminoacetaldehyde dimethyl acetal.

类似技术:

公开号 | 公开日 | 专利标题

JP6324409B2|2018-05-16|Boronic acid derivatives and their therapeutic use

JP6700203B2|2020-05-27|Boronic acid derivatives and their therapeutic use

TWI636036B|2018-09-21|Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b

US10442782B2|2019-10-15|Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

JP6430398B2|2018-11-28|Benzylamine derivatives

US9073825B2|2015-07-07|Methods and intermediates for preparing macrolactams

AU2003208105C1|2009-08-13|Aromatic amino acid derivatives and medicinal compositions

EP1127058B1|2004-09-01|Pyrazolopyridine derivatives as selective cox-2 inhibitors

EP0611756B1|2003-05-07|Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor

US6569855B2|2003-05-27|Substituted cyclic amine metalloprotease inhibitors

US7351724B2|2008-04-01|Oxadiazole ketone inhibitors of fatty acid amide hydrolase

DE69728673T2|2005-03-31|Substituted biphenyl isoxazole sulfonamide

JP4199309B2|2008-12-17|Novel acetamide derivatives and protease inhibition

US6953858B2|2005-10-11|HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

FI112655B|2003-12-31|A process for the preparation of novel therapeutically useful phenylsulfonamide derivatives

KR100368370B1|2003-03-28|Substituted biphenyl isoxazole sulfonamide

ES2269688T3|2007-04-01|Benzoilsulfonamids and sulfonylbenzamidins for use as antitumor agents.

EP1208095B1|2004-05-12|Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes

US6150370A|2000-11-21|1,3-diheterocyclic metalloprotease inhibitors

JP3510955B2|2004-03-29|Improved antiviral compounds

RU2116301C1|1998-07-27|Sulfonamide derivative of isoxazole or its pharmaceutically acceptable salts

JP3277170B2|2002-04-22|Metalloprotease inhibitor

ES2294342T3|2008-04-01|Antitumor benzoilsulfamids.

TW411334B|2000-11-11|Sulfonamide endothelin antagonists

同族专利:

公开号 | 公开日

MXPA01009362A|2002-06-04|

EP1165472A1|2002-01-02|

HU0201320A2|2002-08-28|

CA2367916A1|2000-09-28|

WO2000056685A1|2000-09-28|

US6313308B1|2001-11-06|

EP1165472A4|2002-11-20|

JP2002540088A|2002-11-26|

AU3718900A|2000-10-09|

IL144708D0|2002-06-30|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

法律状态:
1999-03-19|Priority to US12514899P

1999-03-19|Priority to US60/125,148

2000-03-02|Application filed by 스티븐 비. 데이비스, 브리스톨-마이어스스퀴브컴파니

2000-03-02|Priority to PCT/US2000/005521

2002-01-16|Publication of KR20020004974A

优先权:

申请号 | 申请日 | 专利标题

US12514899P| true| 1999-03-19|1999-03-19|

US60/125,148|1999-03-19|

PCT/US2000/005521|WO2000056685A1|1999-03-19|2000-03-02|Methods for the preparation of biphenyl isoxazole sulfonamides|

[返回顶部]